Many drugs are being tested in patients at different stages of the disease, but with a few notable exceptions, results so far have been disappointing. In patients with severe COVID-19, runaway inflammation is a big contributor to the tissue damage we see with this disease. Another class of drugs that you may soon be hearing more about are those targeting complement. THE CONVERSATION